Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
High Dose
100%
Murine Model
100%
Rifamycin
100%
Rifampin
100%
Oral Treatment
100%
Mycobacterium Ulcerans
100%
Rifapentine
83%
Buruli Ulcer
66%
Clarithromycin
33%
Streptomycin
33%
Ceiling Effect
33%
M. Ulcerans
33%
Dose-dependent
33%
Health Systems
16%
Mycobacterium Tuberculosis (M. tb)
16%
Mouse Model
16%
Indirect Costs
16%
Clinical Trials
16%
Clinical Outcomes
16%
Treatment Duration
16%
Dose-ranging
16%
Small Lesions
16%
Skin Tissue
16%
With Disabilities
16%
Soft Tissue Infection
16%
Microbiological Outcome
16%
Social Stigma
16%
Disability Stigma
16%
Highly Efficient
16%
All-oral
16%
Ulcer Treatment
16%
Duration Cost
16%
Medicine and Dentistry
Drug Megadose
100%
Rifampicin
100%
Rifamycin
100%
Mycobacterium ulcerans
100%
Diseases
100%
Oral
100%
Rifapentine
83%
Buruli Ulcer
66%
Streptomycin
33%
Clarithromycin
33%
Ranitidine
33%
Health System
16%
Health Care Cost
16%
Clinical Trial
16%
Body Weight
16%
Treatment Duration
16%
Social Stigma
16%
Soft Tissue Infection
16%
Tuberculosis
16%
Pharmacology, Toxicology and Pharmaceutical Science
Rifampicin
100%
Rifamycin
100%
Mycobacterium ulcerans
100%
Diseases
100%
Rifapentine
83%
Buruli Ulcer
66%
Clarithromycin
33%
Streptomycin
33%
Ranitidine
33%
Clinical Trial
16%
Mouse Model
16%
Soft Tissue Infection
16%
Tuberculosis
16%
Immunology and Microbiology
Drug Megadose
100%
Mycobacterium ulcerans
100%
Rifamycin
100%
Mouse Model
33%
Body Weight
33%
Infectious Disease
33%
Soft Tissue
33%
Infection
33%